Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types.
Collagen
Fibroblast
Prognosis
Serum biomarker
Tumor fibrosis
Journal
Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402
Informations de publication
Date de publication:
25 Mar 2022
25 Mar 2022
Historique:
received:
07
12
2021
accepted:
28
02
2022
revised:
15
02
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
5
4
2022
Statut:
epublish
Résumé
Due to activation of fibroblast into cancer-associated fibroblasts, there is often an increased deposition of extracellular matrix and fibrillar collagens, e.g. type III collagen, in the tumor microenvironment (TME) that leads to tumor fibrosis (desmoplasia). Tumor fibrosis is closely associated with treatment response and poor prognosis for patients with solid tumors. To assure that the best possible treatment option is provided for patients, there is medical need for identifying patients with high (or low) fibrotic activity in the TME. Measuring unique collagen fragments such as the pro-peptides released into the bloodstream during fibrillar collagen deposition in the TME can provide a non-invasive measure of the fibrotic activity. Based on data from 8 previously published cohorts, this review provides insight into the prognostic value of quantifying tumor fibrosis by measuring the pro-peptide of type III collagen in serum of a total of 1692 patients with different solid tumor types and discusses the importance of tumor fibrosis for understanding prognosis and for potentially guiding future drug development efforts that aim at overcoming the poor outcome associated with a fibrotic TME.
Identifiants
pubmed: 35332383
doi: 10.1007/s00018-022-04226-0
pii: 10.1007/s00018-022-04226-0
pmc: PMC8948122
doi:
Substances chimiques
Collagen Type III
0
Peptides
0
Collagen
9007-34-5
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
204Informations de copyright
© 2022. The Author(s).
Références
Nat Med. 2016 Aug;22(8):851-60
pubmed: 27376576
JAMA Oncol. 2019 Jul 01;5(7):1020-1027
pubmed: 31145418
Autoimmun Rev. 2021 Jan;20(1):102706
pubmed: 33188918
Nat Commun. 2018 Nov 8;9(1):4692
pubmed: 30410077
Cancer Immunol Immunother. 2017 Aug;66(8):1037-1048
pubmed: 28451791
Assay Drug Dev Technol. 2013 Mar;11(2):70-92
pubmed: 23046407
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Liver Int. 2020 Apr;40(4):736-750
pubmed: 31997561
Sci Transl Med. 2017 Nov 8;9(415):
pubmed: 29118259
Oncotarget. 2016 Feb 2;7(5):6159-74
pubmed: 26716418
Dev Cell. 2019 May 6;49(3):332-346
pubmed: 31063753
Ann Oncol. 2020 Oct;31(10):1336-1349
pubmed: 32710930
J Immunol. 2020 Sep 1;205(5):1461-1472
pubmed: 32839214
J Clin Invest. 2020 Sep 1;130(9):4704-4709
pubmed: 32749238
J Cell Sci. 2013 Oct 15;126(Pt 20):4647-58
pubmed: 23902685
J Hepatocell Carcinoma. 2020 Nov 09;7:301-313
pubmed: 33204663
Cancer Cell. 2014 Jun 16;25(6):719-34
pubmed: 24856586
Int J Mol Sci. 2018 May 21;19(5):
pubmed: 29883428
Front Mol Biosci. 2020 Jan 31;6:160
pubmed: 32118030
Cancer Cell. 2021 Jun 14;39(6):845-865.e7
pubmed: 34019806
Matrix Biol Plus. 2022 Jan 28;13:100101
pubmed: 35198964
Int J Oncol. 2021 Jul;59(1):
pubmed: 33982770
J Exp Med. 2014 Jul 28;211(8):1503-23
pubmed: 25071162
Nat Rev Nephrol. 2016 Jun;12(6):325-38
pubmed: 27108839
Curr Top Dev Biol. 2018;130:143-191
pubmed: 29853176
Nat Commun. 2020 Sep 9;11(1):4520
pubmed: 32908154
Cancer Cell. 2014 Jun 16;25(6):735-47
pubmed: 24856585
Cancer Biomark. 2015;15(6):783-8
pubmed: 26406420
Cell. 2021 Feb 4;184(3):596-614.e14
pubmed: 33508232
JHEP Rep. 2021 Jul 10;3(4):100317
pubmed: 34466796
Cancer Cell. 2020 Sep 14;38(3):326-333
pubmed: 32750319
Microsc Res Tech. 2010 Feb;73(2):99-108
pubmed: 19658178
Cancers (Basel). 2021 Jul 11;13(14):
pubmed: 34298680
J Am Chem Soc. 2020 Mar 11;142(10):4944-4954
pubmed: 32069041
N Engl J Med. 2015 Mar 19;372(12):1138-49
pubmed: 25785971
Cancer Cell. 2021 Apr 12;39(4):548-565.e6
pubmed: 33667385
J Exp Med. 2017 Mar 6;214(3):579-596
pubmed: 28232471
Biochem J. 2006 Sep 15;398(3):515-9
pubmed: 16771712
Nat Commun. 2018 Aug 29;9(1):3503
pubmed: 30158554
J Immunother Cancer. 2019 Oct 26;7(1):278
pubmed: 31655605
Genes Dev. 2016 May 1;30(9):1002-19
pubmed: 27151975
Mol Cancer Res. 2016 Mar;14(3):287-95
pubmed: 26631572
J Clin Invest. 2018 Jan 2;128(1):16-25
pubmed: 29293090
Front Oncol. 2019 Nov 05;9:1161
pubmed: 31750249
Transl Oncol. 2018 Apr;11(2):528-534
pubmed: 29524830
Int J Cancer. 2018 Dec 1;143(11):3027-3034
pubmed: 29923614
Biochem J. 1985 Nov 15;232(1):145-50
pubmed: 4084223
Nat Rev Mol Cell Biol. 2014 Dec;15(12):786-801
pubmed: 25415508
J Clin Invest. 2021 Jun 1;131(11):
pubmed: 33905375
Cancer Med. 2014 Oct;3(5):1136-45
pubmed: 25044252
Cancer Metastasis Rev. 2020 Sep;39(3):603-623
pubmed: 32447477
J Hepatol. 2019 Mar;70(3):483-493
pubmed: 30414864
Proc Natl Acad Sci U S A. 1987 Jan;84(1):136-40
pubmed: 3467345
Front Oncol. 2020 Jan 24;9:1512
pubmed: 32039007
Clin Cancer Res. 2020 Sep 15;26(18):4842-4851
pubmed: 32586938
Trends Cell Biol. 2008 Nov;18(11):560-74
pubmed: 18848450
Matrix Biol. 2020 Sep;91-92:188-203
pubmed: 32205152
Sci Rep. 2021 Jan 13;11(1):865
pubmed: 33441622
J Cell Biol. 1997 Apr 7;137(1):231-45
pubmed: 9105051
J Exp Clin Cancer Res. 2019 Mar 6;38(1):115
pubmed: 30841909
Cancer Discov. 2020 Feb;10(2):232-253
pubmed: 31699795
J Mammary Gland Biol Neoplasia. 2001 Jul;6(3):299-309
pubmed: 11547899
J Immunother Cancer. 2018 Jul 3;6(1):65
pubmed: 29970158
Biomark Res. 2020 Nov 11;8(1):64
pubmed: 33292666
Cancer Immunol Immunother. 2018 Jan;67(1):1-12
pubmed: 29022089
Physiol Rev. 2021 Jan 1;101(1):147-176
pubmed: 32466724
J Hematol Oncol. 2019 Aug 28;12(1):86
pubmed: 31462327
J Cell Sci. 2009 Sep 1;122(Pt 17):3015-24
pubmed: 19692588
Nat Rev Cancer. 2002 Feb;2(2):91-100
pubmed: 12635172
Adv Drug Deliv Rev. 2017 Nov 1;121:43-56
pubmed: 28736303
Cancer Res. 2011 Jan 15;71(2):303-9
pubmed: 21084269
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Cells. 2019 Jan 23;8(2):
pubmed: 30678058
Front Oncol. 2020 Aug 18;10:1488
pubmed: 33014790
Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):2909-14
pubmed: 21282607
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
Oral Oncol. 2012 Feb;48(2):136-40
pubmed: 21945070
Front Pharmacol. 2019 Jun 14;10:673
pubmed: 31258479
Front Med. 2017 Dec;11(4):522-527
pubmed: 28744793
Sci Transl Med. 2019 Apr 10;11(487):
pubmed: 30971453
Nat Mater. 2021 Jun;20(6):892-903
pubmed: 33495631
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33093157
Mol Cancer. 2021 Oct 11;20(1):131
pubmed: 34635121
J Immunother Cancer. 2018 Dec 19;6(1):152
pubmed: 30567561
Matrix Biol. 2018 Aug;68-69:122-149
pubmed: 29458139
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
Nat Rev Immunol. 2020 Nov;20(11):651-668
pubmed: 32433532
Biochim Biophys Acta. 2013 Jul;1832(7):1049-60
pubmed: 23046809
Clin Biochem. 2021 Nov;97:11-24
pubmed: 34453894
J Transl Med. 2021 Jan 21;19(1):39
pubmed: 33478521
BMC Med. 2008 Apr 28;6:11
pubmed: 18442412
Int J Cancer. 2020 May 15;146(10):2913-2922
pubmed: 31642523
Nature. 2021 May;593(7860):575-579
pubmed: 33981032
J Cell Sci. 2010 Dec 15;123(Pt 24):4195-200
pubmed: 21123617
Sci Rep. 2019 Dec 24;9(1):19761
pubmed: 31875000
Nat Cancer. 2022 Jan;3(1):90-107
pubmed: 35121989
ScientificWorldJournal. 2014 Jan 21;2014:521754
pubmed: 24578639
Respiration. 2014;88(6):487-99
pubmed: 25359084
Am J Transl Res. 2013 Apr 19;5(3):303-15
pubmed: 23634241
J Transl Med. 2020 May 20;18(1):207
pubmed: 32434573
Clin Cancer Res. 2017 Apr 1;23(7):1710-1721
pubmed: 27702820
Front Oncol. 2020 Apr 15;10:397
pubmed: 32351878
Cancers (Basel). 2020 Jun 09;12(6):
pubmed: 32527017
Cancers (Basel). 2022 Feb 06;14(3):
pubmed: 35159087
J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6
pubmed: 23420197
Matrix. 1993 Sep;13(5):381-7
pubmed: 7504165
BMC Gastroenterol. 2015 Sep 02;15:109
pubmed: 26330349
EMBO Rep. 2014 Dec;15(12):1243-53
pubmed: 25381661
NPJ Precis Oncol. 2018 Nov 15;2:25
pubmed: 30456308
Nat Rev Cancer. 2003 Jun;3(6):422-33
pubmed: 12778132
Nat Rev Immunol. 2019 Jun;19(6):369-382
pubmed: 30718830
Nature. 2016 Feb 4;530(7588):42-3
pubmed: 26842052
Aliment Pharmacol Ther. 2020 Jul;52(1):85-97
pubmed: 32419162
Nat Biomed Eng. 2020 May;4(5):531-543
pubmed: 32284554
Cancer Res. 2009 Nov 15;69(22):8594-602
pubmed: 19887621
Gastroenterology. 2015 Apr;148(4):849-50
pubmed: 25724458
Matrix Biol. 2020 Sep;91-92:8-18
pubmed: 32442601
Eur J Clin Invest. 1979 Dec;9(6):451-9
pubmed: 119643